Re: A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy

European Urology

Volumn 61, Issue 3, 2012, Pages 623-624

  Moyad, Mark A ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; LIPID; METFORMIN;

AGED; ANDROGEN DEPRIVATION THERAPY; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXERCISE; GLYCEMIC INDEX; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MALE; NOTE; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; WAIST CIRCUMFERENCE;

EID: 84856369944     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.12.039     Document Type: Note

References (5)

1. K.R. Solomon, and M.R. Freeman The complex interplay between cholesterol and prostate malignancy Urol Clin North Am 38 2011 243 259
2. Diabetes Prevention Program Research Group 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study Lancet 373 2009 1677 1686
3. M. Jalving, J.A. Gietema, and J.D. Lefrandt Metformin: taking away the candy for cancer? Eur J Cancer 46 2010 2369 2380
4. D.A. Galvao, D.R. Taaffe, N. Spry, D. Joseph, and R.U. Newton Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial J Clin Oncol 28 2010 340 347
5. E.D. Crawford, R. Grubb III, and A. Black Comorbidity and mortality results from a randomized prostate cancer screening trial J Clin Oncol 29 2011 355 361